title: Continuous subcutaneous insulin infusion in Italy: third national survey.
abstract: BACKGROUND
  Continuous subcutaneous insulin infusion (CSII) is increasing worldwide, mostly because of improved technology. The aim of this study was to evaluate the current status of CSII in Italy.
  
  
  METHODS
  Physicians from 272 diabetes centers received a questionnaire investigating clinical features, pump technology, and management of patients on CSII.
  
  
  RESULTS
  Two hundred seventeen centers (79.8%) joined the study and, by the end of April 2013, gave information about 10,152 patients treated with CSII: 98.2% with type 1 diabetes mellitus, 81.4% adults, 57% female, and 61% with a conventional pump versus 39% with a sensor-augmented pump. CSII advanced functions were used by 68% of patients, and glucose sensors were used 12 days per month on average. Fifty-eight percent of diabetes centers had more than 20 patients on CSII, but there were differences among centers and among regions. The main indication for CSII was poor glucose control. Dropout was mainly due to pump wearability or nonoptimal glycemic control. Twenty-four hour assistance was guaranteed in 81% of centers. A full diabetes team (physician+nurse+dietician+psychologist) was available in 23% of adult-care diabetes centers and in 53% of pediatric diabetes units.
  
  
  CONCLUSIONS
  CSII keeps increasing in Italy. More work is needed to ensure uniform treatment strategies throughout the country and to improve pump use.
authors.affiliation: 1 Metabolic Diseases, Department of Medicine-DIMED, University of Padua , Padua, Italy .
authors.forename: Daniela
authors.initials: D
authors.lastname: Bruttomesso
authors.forename: Luigi
authors.initials: L
authors.lastname: Laviola
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lepore
authors.forename: Riccardo
authors.initials: R
authors.lastname: Bonfanti
authors.forename: Lutgarda
authors.initials: L
authors.lastname: Bozzetto
authors.forename: Andrea
authors.initials: A
authors.lastname: Corsi
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Blasi
authors.forename: Angela
authors.initials: A
authors.lastname: Girelli
authors.forename: Giorgio
authors.initials: G
authors.lastname: Grassi
authors.forename: Dario
authors.initials: D
authors.lastname: Iafusco
authors.forename: Ivana
authors.initials: I
authors.lastname: Rabbone
authors.forename: Riccardo
authors.initials: R
authors.lastname: Schiaffini
mesh_terms: D000328:Adult; D001786:Blood Glucose; D002648:Child; D003362:Cost-Benefit Analysis; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D019538:Health Care Surveys; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D055104:Infusions, Subcutaneous / Q000706:statistics & numerical data*; D007328:Insulin / Q000008:administration & dosage*; D007558:Italy / Q000453:epidemiology; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin